6533b81ffe1ef96bd1277b7e

RESEARCH PRODUCT

Mortality after in-hospital cardiac arrest in patients with COVID-19: A systematic review and meta-analysis.

Rosa FucàAntonino GiarratanoEnrico BaldiGiulia CatalisanoMariachiara IppolitoSharon EinavClaudia MarinoAndrea Cortegiani

subject

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.medical_treatment030204 cardiovascular system & hematologyEmergency Nursing03 medical and health sciences0302 clinical medicinePrimary outcomeInternal medicineHospital dischargeMedicineHumansIn patientcprCardiopulmonary resuscitationMortalitybusiness.industrySARS-CoV-2Neurological statusMortality rateCOVID-19030208 emergency & critical care medicineCardiac arrestCardiopulmonary ResuscitationHospitalsHeart ArrestEditorialMeta-analysisEmergency MedicineCardiology and Cardiovascular Medicinebusiness

description

Abstract Aim To estimate the mortality rate, the rate of return of spontaneous circulation (ROSC) and survival with favorable neurological outcome in patients with COVID-19 after in-hospital cardiac arrest (IHCA) and attempted cardiopulmonary resuscitation (CPR). Methods PubMed, EMBASE, Web of Science, bioRxiv and medRxiv were surveyed up to 8th February 2021 for studies reporting data on mortality of patients with COVID-19 after IHCA. The primary outcome sought was mortality (in-hospital or at 30 days) after IHCA with attempted CPR. Additional outcomes were the overall rate of IHCA, the rate of non-shockable presenting rhythms, the rate of ROSC and the rate of survival with favorable neurological status. Results Ten articles were included in the systematic review and meta-analysis, for a total of 1179 COVID-19 patients after IHCA with attempted CPR. The estimated overall mortality rate (in-hospital or at 30 days) was 89.9% (95% Predicted Interval [P.I.] 83.1%–94.2%; 1060/1179 patients; I2 = 82%). The estimated rate of non-shockable presenting rhythms was 89% (95% P.I. 82.8%–93.1%; 1022/1205 patients; I2 = 85%), and the estimated rate of ROSC was 32.9% (95% P.I. 26%–40.6%; 365/1205 patients; I2 = 82%). The estimated overall rate of survival with favorable neurological status at 30 days was 6.3% (95% P.I. 4%–9.7%; 50/851 patients; I2 = 48%). Sensitivity analysis showed that COVID-19 patients had higher risk of death after IHCA than non COVID-19 patients (OR 2.34; 95% C.I. 1.37–3.99; number of studies = 3; 1215 patients). Conclusions Although one of three COVID-19 patients undergoing IHCA may achieve ROSC, almost 90% may not survive at 30 days or to hospital discharge.

10.1016/j.resuscitation.2021.04.025https://pubmed.ncbi.nlm.nih.gov/34089773